Topical skin care composition
AssigneeGalderma S.A.
InventorNancy Puglia
Life of this patent
Estimating the term…
Abstract
A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.
Claims14
A process of making a pharmaceutical composition for topical application, the composition being an emulsion comprising water and at least one active ingredient selected from the group consisting of fluocinolone acetonide, hydroquinone and tretinoin, the process comprising:
- (a) combining water and at least one hydrophilic compound while heating at a temperature in the range of 75° C. to 80° C. to form an aqueous phase;
- (b) combining at least two hydrophobic compounds while heating at a temperature in the range of 75° C. to 80° C. to form a non-aqueous phase;
- (c) combining the aqueous phase and non-aqueous phase to form a biphasic mixture;
- (d) stirring and cooling the biphasic mixture to a temperature in the range of 68° C. to 72° C., then adding at least one active ingredient;
- (e) while stirring and cooling, adding at least one emulsifier;
- and
- (f) homogenizing the mixture to form the emulsion.
A pharmaceutical composition for topical application, the composition being an emulsion comprising water and at least one active ingredient selected from the group consisting of fluocinolone acetonide, hydroquinone and tretinoin, the composition made by a process comprising the steps of:
- (a) combining water and at least one hydrophilic compound while heating at a temperature in the range of 75° C. to 80° C. to form an aqueous phase;
- (b) combining at least two hydrophobic compounds while heating at a temperature in the range of 75° C. to 80° C. to form a non-aqueous phase;
- (c) combining the aqueous phase and non-aqueous phase to form a biphasic mixture;
- (d) stirring and cooling the biphasic mixture to a temperature in the range of 68° C. to 72° C., then adding at least one active ingredient;
- (e) while stirring and cooling, adding at least one emulsifier;
- and
- (f) homogenizing the mixture to form the emulsion.
A pharmaceutical composition, consisting essentially of 0.01 weight % fluocinolone acetonide;
- 4 weight % hydroquinone;
- 0.05 weight % tretinoin;
- 0.04 weight % butylated hydroxytoluene;
- 4 weight % cetyl alcohol;
- 0.05 weight % citric acid;
- 4 weight % glycerin;
- 3 weight % magnesium aluminum silicate;
- 5 weight % methyl gluceth;
- 0.18 weight % methylparaben;
- 3.5 weight % glyceryl stearate, polyethylene glycol (PEG) stearate or a combination thereof, 0.02 weight % propylparaben, 0.2 weight % sodium metabisulfite, 3 weight % stearic acid and 4 weight % stearyl alcohol.
Dependencies are inferred from the claim text.